Back to search
FDAFDA · Food and drugs·Recall number D-0454-2023

DIBUCAINE 1% HEMORRHOIDAL OINTMENT, 1 oz. (28 gm), Manufactured for: Akron Pharma Inc. Fairfield NJ 07004, NDC 71399-2829-1

Published March 15, 2023 · Recall initiated: February 17, 2023

Summary

FDA records drug Class III recall D-0454-2023, published March 15, 2023 and initiated February 17, 2023. Recalling firm: Akron Pharma, Inc.; Status: Terminated; Reported quantity: 4,416 tubes; Lot: Lot #: 2206016, Exp. date 05/2024. Class III means the product is not likely to cause adverse health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Labeling: Incorrect or Missing Lot and/or Exp Date

What to do

Voluntary: Firm initiated · Letter

Get an email if DIBUCAINE has another recall

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Brand
DIBUCAINE
Manufacturer
Akron Pharma, Inc.
Distributor
Nationwide within the United States
Lot
Lot #: 2206016, Exp. date 05/2024
Risk classification
Class III
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was DIBUCAINE 1% HEMORRHOIDAL OINTMENT, 1 oz. (28 gm), Manufactured for: Akron Pharma Inc. Fairfield NJ 07004, NDC 71399-2829-1 recalled?

Yes. FDA published recall D-0454-2023 on March 15, 2023. Reported hazard: Labeling: Incorrect or Missing Lot and/or Exp Date

What should I do if I have this product?

Voluntary: Firm initiated · Letter

How do I know if my unit is part of the recall?

Compare your product details with the notice. Brand: DIBUCAINE.